GSTT2
Glutathione S-transferase theta-2
Also known as: GST2_HUMAN
Protein identityUniProt · HPA
- UniProt accession
- P0CG29
- Gene
- GSTT2
- Canonical length
- 244 aa
- Protein class
- Metabolic proteins, Predicted intracellular proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
No narrative summary is available for GSTT2 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
244 residues, UniProt reviewed canonical sequence.
>P0CG29|GSTT2
1 MGLELFLDLV SQPSRAVYIF AKKNGIPLEL RTVDLVKGQH KSKEFLQINS LGKLPTLKDG
61 DFILTESSAI LIYLSCKYQT PDHWYPSDLQ ARARVHEYLG WHADCIRGTF GIPLWVQVLG
121 PLIGVQVPKE KVERNRTAMD QALQWLEDKF LGDRPFLAGQ QVTLADLMAL EELMQPVALG
181 YELFEGRPRL AAWRGRVEAF LGAELCQEAH SIILSILEQA AKKTLPTPSP EAYQAMLLRI
241 ARIPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GSTT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.25
- Highest tissue expression
- 3.3 nTPM
Expression across tissuesHPA
Tissue
- skin: 3.3 nTPM
- adrenal gland: 1.5 nTPM
- seminal vesicle: 1 nTPM
- skeletal muscle: 0.9 nTPM
- salivary gland: 0.8 nTPM
- ovary: 0.7 nTPM
Single-cell type
- melanocytes: 5.6 nCPM
- astrocytes: 4.7 nCPM
- lacrimal acinar cells: 4.5 nCPM
- oligodendrocyte progenitor cells: 3.6 nCPM
- ependymal cells: 3.1 nCPM
- conjunctival goblet cells: 2.9 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 2.6 nTPM
- hypothalamus: 1.9 nTPM
- white matter: 1.9 nTPM
- pons: 1.6 nTPM
- midbrain: 1.5 nTPM
- thalamus: 1.5 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GSTT2.
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 17 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.61
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.89
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Glutathione S-transferase, N-terminal
- Glutathione S-transferase, C-terminal
- Glutathione S-transferase, C-terminal-like
- Thioredoxin-like superfamily
- Glutathione S-transferase, C-terminal domain superfamily
- Glutathione S-transferase Theta, N-terminal
- Glutathione S-transferase Theta, C-terminal
- Glutathione transferase family
- Glutathione S-transferase Theta
- Glutathione S-transferase, C-terminal domain
- Glutathione S-transferase, N-terminal domain
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GSTT2 as an antibody target. Whether an autoantibody or antibody against GSTT2 could matter depends on whether native GSTT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GSTT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label GSTT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...